VACCINE TRIALS IN MACAQUES WITH VACCINIA-SIV RECOMBINANTS

这项计划的目标是研制出一种有效的疫苗。 人类免疫抑制病毒(HIV-1)感染及其结果 获得性免疫缺陷综合症(艾滋病)。我们的策略是 双重：(1)利用表达重组痘苗病毒 HIV-1或猿猴免疫缺陷病毒(SIV)抗原诱导 免疫，以及(2)利用SIV模型评估 以不同的重组疫苗原型为指标 相应的重组HIV-1疫苗性能。 对重组SIV和HIV-1疫苗的评估将包括 疫苗在不同实验动物体内抗原性的测定 物种(包括通过体液和细胞测定的灵长类动物- 介导性免疫反应；保护性免疫和改善性 重组疫苗在灵长类动物体内接种前后的特性 对SIV的挑战：感染SIV的牛痘病毒载体的毒性 灵长类动物.HIV-1最终疫苗在灵长类动物中的安全性评价 候选人。 分配给此特定研究项目的研究，作为 国家获得者合作疫苗开发小组 免疫缺陷综合征(NCVDG)将在EG&G Mason进行 新英格兰地区灵长类动物研究所(EG&G MRI) 研究中心(NERPRC)和马萨诸塞大学 医学院(UMMS)。这项研究将由 马萨诸塞州伍斯特EG&G MRI项目负责人与 校长提供的研究和行政支持 马萨诸塞州剑桥市应用生物技术的研究员。

The goal of this program is to develop an effective vaccine against human immunosuppressive virus (HIV-1) infection and the resultant Acquired Immunodeficiency Syndrome (AIDS). The strategy is twofold: (1) to utilize recombinant vaccinia viruses expressing HIV-1 or Simian Immunodeficiency Virus (SIV) antigens to induce immunity, and (2) to utilize the SIV model for evaluation of different recombinant vaccine prototypes as a indicator for corresponding recombinant HIV-1 vaccine performance. Evaluation of recombinant SIV and HIV-1 vaccines will include determination of: vaccine antigenicity in various laboratory animal species (including primates by determination of humoral and cell- mediated immune responses; protective immunity and meliorative properties of recombinant vaccines in primates before and after challenge with SIV: toxicity of vaccinia vectors in SIV-infected primates; safety evaluation in primates of final HIV-1 vaccine candidates. Research assigned to this specific Research Project as a part of the National Cooperative Vaccine Development Group for the Acquired Immunodeficiency Syndrome (NCVDG) will be performed at EG&G Mason Research Institute (EG&G MRI), the New England Regional Primate Research Center (NERPRC), and the University of Massachusetts Medical School (UMMS). This research will be coordinated by the Project Leader at EG&G MRI, Worcester, MA in collaboration with research and administrative support provided by the Principal Investigator at Applied bioTechnology, Cambridge, MA.